Amneal Appoints Deborah M. Autor to Board of Directors
August 03 2022 - 8:00AM
Business Wire
- Adds new independent director with deep biopharmaceutical
industry expertise in quality, regulatory and policy
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the
“Company”) today announced that Deborah M. Autor has been appointed
to the Company’s Board of Directors, effective July 29, 2022.
Chirag and Chintu Patel, Co-Chief Executive Officers, stated,
“Deb brings decades of global public and private expertise in the
biopharmaceutical sector to our board at an important time of
growth for Amneal. She has a proven track record of service and
impact throughout her distinguished career in quality, regulatory,
and policy. We are delighted to welcome Deb to the board and look
forward to working closely with her as we execute our strategy and
expand our business into new and more complex high growth
areas.”
Most recently, Ms. Autor held global quality and regulatory
leadership roles at AstraZeneca and Mylan N.V. From 2019 to 2021,
Ms. Autor was Global Head of Regulatory Excellence at AstraZeneca,
where she led regulatory operations, policy and intelligence for
their submissions globally. Prior to that, Ms. Autor was at Mylan
N.V. from 2013 to 2019, where she was Head of Strategic Global
Quality and Regulatory Policy and Head of Global Quality. Prior to
her leadership within the industry, she served at the U.S. Food and
Drug Administration (“FDA”) for over a decade, including as Deputy
Commissioner for Global Regulatory Operations and Policy where she
oversaw all FDA inspections, criminal investigations and
international operations for human and veterinary drugs, biologics,
medical devices, tobacco and food. Before that, Ms. Autor served as
Director of the Office of Compliance of the Center for Drug
Evaluation and Research, leading enforcement and policymaking for
compliance with all drug requirements, including, drug approval;
current good manufacturing practices (GMP); human subject
protection and bioresearch monitoring (GCP); import and export; and
recalls. During her time at the FDA, she won several public service
awards. Before joining the FDA, Ms. Autor was a Trial Attorney in
the Office of Consumer Litigation of the U.S. Department of
Justice, where she litigated civil and criminal cases on behalf of
the FDA. She received a Juris Doctor, Magna Cum Laude, from Boston
University School of Law and a Bachelor of Arts in Psychology from
Columbia University, Barnard College. Ms. Autor also has diverse
board experience, including currently serving as a Board Director
for Pardes Biosciences, Inc. and Chair of Board for the FDA Alumni
Association.
As a result of Ms. Autor’s appointment, the Amneal Board will
comprise of eleven directors.
About Amneal
Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in
Bridgewater, NJ, is a fully integrated essential medicines company.
We make healthy possible through the development, manufacturing,
and distribution of generic and specialty pharmaceuticals,
primarily within the United States. The Company has a diverse
portfolio of over 250 products in its Generics segment and is
expanding across a broad range of complex products and therapeutic
areas, including injectables and biosimilars. In its Specialty
segment, Amneal has a growing portfolio of branded pharmaceutical
products focused primarily on central nervous system and endocrine
disorders, with a pipeline focused on unmet needs. Through its
AvKARE segment, the Company is a distributor of pharmaceuticals and
other products for the U.S. federal government, retail, and
institutional markets. For more, please visit www.amneal.com.
Cautionary Statement on Forward-Looking Statements
Certain statements contained herein, regarding matters that are
not historical facts, may be forward-looking statements (as defined
in the U.S. Private Securities Litigation Reform Act of 1995). Such
forward-looking statements include statements regarding
management’s intentions, plans, strategies, beliefs, expectations
or forecasts for the future, including among other things: product
research and development; discussions of future operations;
expected operating results and financial performance, including pro
forma results; impact of acquisitions and dispositions, and
estimated returns or assumptions underlying acquisitions and
dispositions; the Company’s strategy for growth; regulatory
approvals and actions; market position, saturation, and
expenditures. Words such as “plans,” “expects,” “will,”
“anticipates,” “estimates” and similar words are intended to
identify estimates and forward-looking statements.
The reader is cautioned not to rely on these forward-looking
statements. These forward-looking statements are based on current
expectations of future events. If the underlying assumptions prove
inaccurate or known or unknown risks or uncertainties materialize,
actual results could vary materially from the expectations and
projections of the Company.
Such risks and uncertainties include, but are not limited to:
our ability to successfully develop, license, acquire and
commercialize new products on a timely basis; the competition we
face in the pharmaceutical industry in general, including from
brand and generic drug product companies, and the impact of that
competition on our ability to execute on pricing strategies; our
ability to obtain exclusive marketing rights for our products; our
ability to manage our growth through acquisitions and otherwise;
our dependence on the sales of a limited number of products for a
substantial portion of our total revenues; the continuing trend of
consolidation of certain customer groups; our dependence on
third-party suppliers and distributors for raw materials for our
products and certain finished goods and any associated supply chain
disruptions; litigation outcomes, including intellectual property
disputes or other legal efforts to prevent or curb Amneal’s ability
to sell its products; the impact of severe weather; the impact of
the ongoing COVID-19 pandemic; risks related to federal regulation
of arrangements between manufacturers of branded and generic
products; our reliance on certain licenses to proprietary
technologies from time to time; the significant amount of resources
we expend on research and development; the risk of product
liability and other claims against us by consumers and other third
parties; risks related to changes in the regulatory environment,
including U.S. federal and state laws related to healthcare fraud
abuse and health information privacy and security and changes in
such laws; changes to FDA product approval requirements; the impact
of healthcare reform and changes in coverage and reimbursement
levels by governmental authorities and other third-party payers;
our dependence on third-party agreements for a portion of our
product offerings; the impact of global economic conditions,
including any economic effects stemming from adverse geopolitical
events, an economic downturn and inflation rates; our ability to
identify, make and integrate acquisitions or investments in
complementary businesses and products on advantageous terms; our
substantial amount of indebtedness and our ability to generate
sufficient cash to service our indebtedness in the future, and the
impact of interest rate fluctuations on such indebtedness; our
obligations under a tax receivable agreement may be significant;
and the high concentration of ownership of our Class A Common Stock
and the fact that we are controlled by the Amneal Group. The
forward-looking statements contained herein are also subject
generally to other risks and uncertainties that are described from
time to time in the Company’s filings with the Securities and
Exchange Commission, including under Item 1A, “Risk Factors” in the
Company’s most recent Annual Report on Form 10-K and in its
subsequent reports on Forms 10-Q and 8-K. Investors are cautioned
not to place undue reliance on any such forward-looking statements,
which speak only as of the date they are made. Forward-looking
statements included herein speak only as of the date hereof and we
undertake no obligation to revise or update such statements to
reflect the occurrence of events or circumstances after the date
hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220803005042/en/
Anthony DiMeo Head of Investor Relations
anthony.dimeo@amneal.com
Amneal Pharmaceuticals (NYSE:AMRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amneal Pharmaceuticals (NYSE:AMRX)
Historical Stock Chart
From Apr 2023 to Apr 2024